Cardiovascular risk assessment with the American Heart Association calculator in type 2 diabetes patients: A comparison of empagliflozin indications based on American and European guidelines in southeast of Iran in 2023

BACKGROUND: This study uses the AHA Risk Calculator to initiate empagliflozin in diabetic patients at risk of cardiovascular disease by comparing the threshold to current guidelines. AIM: The purpose of this study is to use the American Heart Association’s Cardiovascular Risk Calculator to initiate empagliflozin in patients at cardiovascular risk and to determine an appropriate threshold for initiation of this drug compared to current European and American guidelines for the treatment of diabetes mellitus. MATERIALS AND METHODS: Information was collected on 800 patients with type 2 diabetes mellitus aged 40 to 79 years and aged 40 to 79 years in the city of Kerman. Patients with indications to start empagliflozin were identified in accordance with the latest European and American guidelines. Using the American Heart Association’s 10-year Cardiovascular Disease Risk Calculator, the patients’ scores were calculated. RESULTS: Of the 800 patients, 435 patients had indications for empagliflozin as recommended. Patients who were recommended to initiate treatment with this medication exhibited a notably elevated likelihood of developing cardiovascular disease. The incidence of risk factors for cardiovascular issues was assessed, with nephropathy, retinopathy, and stroke being the most closely linked to the commencement of empagliflozin as per recommendations in diabetes management guidelines. CONCLUSION: The American Heart Association calculator can be used to start empagliflozin with a threshold of 6% in women and 6.5% in men.